Marker Therapeutics
MRKR
About: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Employees: 5
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
3% more capital invested
Capital invested by funds: $5.04M [Q1] → $5.18M (+$145K) [Q2]
6% less funds holding
Funds holding: 32 [Q1] → 30 (-2) [Q2]
8.38% less ownership
Funds ownership: 38.26% [Q1] → 29.87% (-8.38%) [Q2]
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Financial journalist opinion
Based on 3 articles about MRKR published over the past 30 days
